Tumors characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) are classified as triple‐negative breast cancer (TNBC), accounting for approximately 15%–20% of all breast cancer cases [1]. This evidence concerns the gene ERBB2 and breast carcinoma.